CO6811816A2 - Composiciones que contienen, métodos que involucran, y usos de derivados de dolastatina unidos a aminiácidos no naturales - Google Patents
Composiciones que contienen, métodos que involucran, y usos de derivados de dolastatina unidos a aminiácidos no naturalesInfo
- Publication number
- CO6811816A2 CO6811816A2 CO13280266A CO13280266A CO6811816A2 CO 6811816 A2 CO6811816 A2 CO 6811816A2 CO 13280266 A CO13280266 A CO 13280266A CO 13280266 A CO13280266 A CO 13280266A CO 6811816 A2 CO6811816 A2 CO 6811816A2
- Authority
- CO
- Colombia
- Prior art keywords
- involve
- methods
- amino acids
- compositions containing
- unnatural amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from kidney or bladder cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Compression Of Band Width Or Redundancy In Fax (AREA)
- Polyamides (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161491146P | 2011-05-27 | 2011-05-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6811816A2 true CO6811816A2 (es) | 2013-12-16 |
Family
ID=47259774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO13280266A CO6811816A2 (es) | 2011-05-27 | 2013-11-28 | Composiciones que contienen, métodos que involucran, y usos de derivados de dolastatina unidos a aminiácidos no naturales |
Country Status (22)
Country | Link |
---|---|
US (4) | US9796754B2 (es) |
EP (2) | EP2714684B1 (es) |
JP (4) | JP6581774B2 (es) |
KR (4) | KR102030856B1 (es) |
CN (4) | CN110078787A (es) |
AU (4) | AU2012262560B2 (es) |
BR (1) | BR112013030372A2 (es) |
CA (1) | CA2837586C (es) |
CL (1) | CL2013003406A1 (es) |
CO (1) | CO6811816A2 (es) |
CR (1) | CR20130667A (es) |
DK (1) | DK2714684T3 (es) |
EA (1) | EA201391756A1 (es) |
EC (1) | ECSP13013115A (es) |
ES (1) | ES2690993T3 (es) |
GT (1) | GT201300295A (es) |
IL (3) | IL229505A (es) |
MX (1) | MX359217B (es) |
NI (1) | NI201300130A (es) |
PE (1) | PE20140784A1 (es) |
WO (1) | WO2012166560A1 (es) |
ZA (1) | ZA201309654B (es) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
EP4302783A3 (en) | 2010-08-17 | 2024-03-13 | Ambrx, Inc. | Modified relaxin polypeptides and their uses |
MX371526B (es) * | 2011-05-27 | 2020-01-31 | Ambrx Inc | Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales. |
CN110078787A (zh) * | 2011-05-27 | 2019-08-02 | Ambrx 公司 | 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途 |
US20130190248A1 (en) * | 2011-07-26 | 2013-07-25 | Agensys, Inc. | Substituted peptide analogs |
CN104640572B (zh) | 2012-05-15 | 2018-04-27 | 索伦托医疗有限公司 | 药物偶联物,偶联方法,及其用途 |
US10800856B2 (en) * | 2012-06-07 | 2020-10-13 | Ambrx, Inc. | Prostate-specific membrane antigen antibody drug conjugates |
SG11201408494UA (en) * | 2012-06-19 | 2015-02-27 | Ambrx Inc | Anti-cd70 antibody drug conjugates |
US10226535B2 (en) | 2012-12-10 | 2019-03-12 | Mersana Therapeutics, Inc. | Auristatin compounds and conjugates thereof |
WO2014153164A1 (en) | 2013-03-14 | 2014-09-25 | The California Institute For Biomedical Research | Targeting agent antibody conjugates and uses thereof |
JP2016516035A (ja) * | 2013-03-15 | 2016-06-02 | ノバルティス アーゲー | 細胞増殖阻害剤およびそれらのコンジュゲート |
KR102178606B1 (ko) | 2013-03-15 | 2020-11-13 | 자임워크스 인코포레이티드 | 세포독성 및 유사분열-억제 화합물, 및 이를 사용하는 방법 |
FR3005051A1 (fr) * | 2013-04-25 | 2014-10-31 | Pf Medicament | Derives de la dolastatine 10 et d'auristatines |
PL2991683T3 (pl) * | 2013-05-02 | 2020-03-31 | Glykos Finland Oy | Koniugaty glikoproteiny lub glikanu z toksycznym ładunkiem |
CA2927543C (en) | 2013-10-15 | 2021-07-20 | The California Institute For Biomedical Research | Peptidic chimeric antigen receptor t cell switches and uses thereof |
SG11201604879QA (en) | 2013-10-15 | 2016-07-28 | Sorrento Therapeutics Inc | Drug-conjugates with a targeting molecule and two different drugs |
NZ717668A (en) | 2013-10-15 | 2024-03-22 | Seagen Inc | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics |
CN103665104B (zh) * | 2013-12-09 | 2015-05-20 | 天津市康信医药科技有限公司 | 一种mmaf中间体五肽的合成方法 |
MX2016007865A (es) | 2013-12-17 | 2017-01-11 | Novartis Ag | Peptidos citotoxicos y conjugados de los mismos. |
KR102384740B1 (ko) | 2013-12-27 | 2022-04-07 | 자임워크스 인코포레이티드 | 약물 접합체를 위한 설폰아마이드-함유 연결 시스템 |
KR102459647B1 (ko) | 2014-04-25 | 2022-10-26 | 피에르 파브르 메디카먼트 | 항체-약물-결합체 및 암의 치료를 위한 그의 용도 |
CN106456800B (zh) | 2014-04-25 | 2018-05-01 | 皮埃尔法布雷医药公司 | Igf-1r抗体-药物-缀合物和其用于治疗癌症的用途 |
AU2015273098B2 (en) | 2014-06-13 | 2018-05-10 | Novartis Ag | Auristatin derivatives and conjugates thereof |
US10973920B2 (en) | 2014-06-30 | 2021-04-13 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
CN113416229A (zh) | 2014-09-17 | 2021-09-21 | 酵活有限公司 | 细胞毒性和抗有丝分裂化合物、及其使用方法 |
MX2017007169A (es) | 2014-12-03 | 2018-05-02 | Genentech Inc | Compuestos de amina cuaternaria y conjugados de anticuerpofármaco de los mismos. |
CA2975383C (en) | 2015-01-28 | 2023-09-12 | Sorrento Therapeutics, Inc. | Antibody drug conjugates comprising dolastatin derivatives |
MX2017011380A (es) | 2015-03-09 | 2018-04-26 | Agensys Inc | Conjugados anticuerpo-farmaco (adc) que se ligan a proteinas flt3. |
US10800828B2 (en) | 2015-03-26 | 2020-10-13 | The Scripps Research Institute | Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer |
WO2016168773A2 (en) | 2015-04-15 | 2016-10-20 | The California Institute For Biomedical Research | Optimized pne-based chimeric receptor t cell switches and uses thereof |
CN105949277B (zh) * | 2015-05-05 | 2019-03-01 | 成都永泰诺科技有限公司 | 一种抗肿瘤化合物及其用途 |
TWI618697B (zh) | 2015-11-03 | 2018-03-21 | 財團法人工業技術研究院 | 化合物、連接子-藥物、及配體-藥物耦合體 |
US10548986B2 (en) | 2016-03-02 | 2020-02-04 | Eisai R&D Management Co., Ltd. | Eribulin-based antibody-drug conjugates and methods of use |
CA3017527A1 (en) | 2016-03-25 | 2017-09-28 | Seattle Genetics, Inc. | Process for the preparation of pegylated drug-linkers and intermediates thereof |
CA3040343A1 (en) | 2016-10-19 | 2018-04-26 | California Institute For Biomedical Research | Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof |
TW201837051A (zh) | 2017-02-08 | 2018-10-16 | 美商必治妥美雅史谷比公司 | 包含藥物動力學增強劑之經修飾之鬆弛素(relaxin)多肽及其用途 |
JP2020512312A (ja) | 2017-03-24 | 2020-04-23 | シアトル ジェネティックス, インコーポレイテッド | グルクロニド薬物−リンカーの調製のためのプロセスおよびその中間体 |
MX2020004691A (es) | 2017-11-07 | 2020-08-20 | Regeneron Pharma | Enlazadores hidrofilicos para conjugados anticuerpo-farmaco. |
KR20200094185A (ko) * | 2017-11-30 | 2020-08-06 | 시애틀 지네틱스, 인크. | 약물 링커 화합물의 제조방법 |
CN111989138B (zh) | 2018-03-29 | 2024-02-09 | Ambrx公司 | 人源化抗前列腺特异性膜抗原(psma)抗体药物缀合物 |
CN109232712B (zh) * | 2018-08-21 | 2021-08-03 | 联宁(苏州)生物制药有限公司 | 一种用于抗体药物偶联物的中间体的制备方法 |
WO2020047176A1 (en) | 2018-08-28 | 2020-03-05 | Ambrx, Inc. | Anti-cd3 antibody folate bioconjugates and their uses |
BR112022001054A2 (pt) * | 2019-08-21 | 2022-03-15 | Kalvista Pharmaceuticals Ltd | Inibidores enzimáticos |
JP2022550434A (ja) | 2019-10-04 | 2022-12-01 | ティーエーイー ライフ サイエンシーズ | Fc変異および部位特異的コンジュゲーション特性を含む抗体組成物 |
WO2021173889A1 (en) | 2020-02-26 | 2021-09-02 | Ambrx, Inc. | Uses of anti-cd3 antibody folate bioconjugates |
WO2023000171A1 (zh) * | 2021-07-20 | 2023-01-26 | 浙江新码生物医药有限公司 | 一种含有抗her2-药物偶联物的冻干组合物、冻干制剂及其制备方法和用途 |
WO2023033129A1 (ja) | 2021-09-03 | 2023-03-09 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2024077277A1 (en) | 2022-10-07 | 2024-04-11 | Ambrx, Inc. | Drug linkers and antibody conjugates thereof |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2504010B1 (fr) | 1981-04-15 | 1985-10-25 | Sanofi Sa | Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation |
US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
US4542225A (en) | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
US4659839A (en) | 1984-10-10 | 1987-04-21 | Mallinckrodt, Inc. | Coupling agents for radiolabeled antibody fragments |
DE3680924D1 (de) | 1985-01-14 | 1991-09-26 | Neorx Corp | Metall-radionuklid markiertes protein fuer diagnose und therapie. |
US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
US4699784A (en) | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
US4816444A (en) * | 1987-07-10 | 1989-03-28 | Arizona Board Of Regents, Arizona State University | Cell growth inhibitory substance |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
US5831002A (en) * | 1992-05-20 | 1998-11-03 | Basf Aktiengesellschaft | Antitumor peptides |
US6034065A (en) * | 1992-12-03 | 2000-03-07 | Arizona Board Of Regents | Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10 |
US5635483A (en) * | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5599902A (en) * | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
DE69921102T2 (de) | 1998-03-05 | 2006-02-02 | Chiron Corp., Emeryville | Verfahren zur verbesserung der serum-halbwertszeit von biologisch aktiven molekülen |
CN1762990A (zh) * | 1999-06-08 | 2006-04-26 | 拉卓拉药物公司 | 包含氨基氧基的化合价平台分子 |
US6323315B1 (en) * | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
MXPA02012438A (es) * | 2000-06-16 | 2004-09-06 | Dept Of Radiation Oncology Uni | Columnas extracorporeas para uso repetido, cargadas con conjugados de ligando-dibiotina. |
IL158418A0 (en) | 2001-04-19 | 2004-05-12 | Scripps Research Inst | In vivo incorporation of unnatural amino acids |
US6649402B2 (en) | 2001-06-22 | 2003-11-18 | Wisconsin Alumni Research Foundation | Microfabricated microbial growth assay method and apparatus |
US6737409B2 (en) | 2001-07-19 | 2004-05-18 | Hoffmann-La Roche Inc. | Dolastatin 10 derivatives |
EP1482972A4 (en) * | 2001-11-20 | 2005-11-23 | Seattle Genetics Inc | TREATMENT OF IMMUNOLOGICAL DISORDERS USING ANTI-CD30 ANTIBODIES |
EP1545613B9 (en) * | 2002-07-31 | 2012-01-25 | Seattle Genetics, Inc. | Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
CA2508939A1 (en) | 2002-12-22 | 2004-07-15 | The Scripps Research Institute | Protein arrays |
ATE472338T1 (de) | 2003-02-20 | 2010-07-15 | Seattle Genetics Inc | Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs |
CN107213469A (zh) * | 2003-11-06 | 2017-09-29 | 西雅图基因公司 | 能够与配体偶联的单甲基缬氨酸化合物 |
CN1960965A (zh) * | 2004-06-02 | 2007-05-09 | 霍夫曼-拉罗奇有限公司 | 氨基-烷氧基-庚酸烷基酯的合成 |
US7807619B2 (en) | 2004-11-01 | 2010-10-05 | The Regents Of The University Of California | Compositions and methods for modification of biomolecules |
PL1912677T3 (pl) * | 2005-06-20 | 2014-03-31 | Psma Dev Company L L C | Koniugaty przeciwciało PSMA-lek |
PL1954710T3 (pl) * | 2005-11-08 | 2011-09-30 | Ambrx Inc | Przyspieszacze do modyfikacji aminokwasów niewystępujących w przyrodzie i polipeptydów zbudowanych z aminokwasów nie występujących w przyrodzie |
US7750116B1 (en) * | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
WO2009117531A1 (en) * | 2008-03-18 | 2009-09-24 | Seattle Genetics, Inc. | Auristatin drug linker conjugates |
BRPI1013645A2 (pt) * | 2009-03-06 | 2019-07-02 | Agensys Inc | conjugado de fármaco anticorpo e sua composição farmacêutica |
MX2011010265A (es) * | 2009-04-01 | 2011-10-11 | Genentech Inc | Anticuerpos anti-fcrh5 e inmunoconjugados y metodos de uso. |
US8521087B2 (en) | 2009-07-15 | 2013-08-27 | Lg Electronics Inc. | System and method for cognitive radio transmission |
JP2013505944A (ja) * | 2009-09-24 | 2013-02-21 | シアトル ジェネティックス, インコーポレイテッド | Dr5リガンド薬物結合体 |
US9073969B2 (en) * | 2009-11-16 | 2015-07-07 | Centre National de la Recherche Scientifique—CNRS | Compounds and methods for purifying peptides produced by solid phase peptide synthesis |
ES2744226T3 (es) * | 2011-05-08 | 2020-02-24 | Legochem Biosciences Inc | Conjugados de proteína-agente activo y método para preparar los mismos |
CN110078787A (zh) | 2011-05-27 | 2019-08-02 | Ambrx 公司 | 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途 |
MX371526B (es) * | 2011-05-27 | 2020-01-31 | Ambrx Inc | Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales. |
-
2012
- 2012-05-24 CN CN201811251860.7A patent/CN110078787A/zh active Pending
- 2012-05-24 DK DK12793246.5T patent/DK2714684T3/en active
- 2012-05-24 AU AU2012262560A patent/AU2012262560B2/en active Active
- 2012-05-24 CN CN201811251863.0A patent/CN110078788B/zh active Active
- 2012-05-24 CN CN202110801039.3A patent/CN113527414A/zh active Pending
- 2012-05-24 KR KR1020137033072A patent/KR102030856B1/ko active IP Right Grant
- 2012-05-24 EA EA201391756A patent/EA201391756A1/ru unknown
- 2012-05-24 KR KR1020197028781A patent/KR102179369B1/ko active IP Right Grant
- 2012-05-24 CN CN201280036296.1A patent/CN103717595A/zh active Pending
- 2012-05-24 ES ES12793246.5T patent/ES2690993T3/es active Active
- 2012-05-24 CA CA2837586A patent/CA2837586C/en active Active
- 2012-05-24 KR KR1020207032063A patent/KR20200128601A/ko active Application Filing
- 2012-05-24 WO PCT/US2012/039472 patent/WO2012166560A1/en active Application Filing
- 2012-05-24 EP EP12793246.5A patent/EP2714684B1/en active Active
- 2012-05-24 PE PE2013002721A patent/PE20140784A1/es not_active Application Discontinuation
- 2012-05-24 JP JP2014512124A patent/JP6581774B2/ja active Active
- 2012-05-24 BR BR112013030372A patent/BR112013030372A2/pt not_active Application Discontinuation
- 2012-05-24 KR KR1020217026203A patent/KR102356286B1/ko active IP Right Grant
- 2012-05-24 MX MX2013013683A patent/MX359217B/es active IP Right Grant
- 2012-05-24 US US14/122,672 patent/US9796754B2/en active Active
- 2012-05-24 EP EP18185522.2A patent/EP3470413A3/en active Pending
-
2013
- 2013-11-19 IL IL229505A patent/IL229505A/en active IP Right Grant
- 2013-11-25 GT GT201300295A patent/GT201300295A/es unknown
- 2013-11-26 NI NI201300130A patent/NI201300130A/es unknown
- 2013-11-27 CL CL2013003406A patent/CL2013003406A1/es unknown
- 2013-11-28 CO CO13280266A patent/CO6811816A2/es unknown
- 2013-12-17 CR CR20130667A patent/CR20130667A/es unknown
- 2013-12-20 ZA ZA2013/09654A patent/ZA201309654B/en unknown
- 2013-12-26 EC ECSP13013115 patent/ECSP13013115A/es unknown
-
2016
- 2016-06-28 AU AU2016204454A patent/AU2016204454B2/en active Active
-
2017
- 2017-09-12 US US15/702,682 patent/US10954270B2/en active Active
- 2017-10-03 IL IL254879A patent/IL254879B/en active IP Right Grant
-
2018
- 2018-02-16 JP JP2018026159A patent/JP6781721B2/ja active Active
- 2018-05-23 AU AU2018203639A patent/AU2018203639B2/en active Active
-
2020
- 2020-04-23 IL IL274204A patent/IL274204B/en unknown
- 2020-06-04 JP JP2020097905A patent/JP2020147587A/ja active Pending
- 2020-08-11 AU AU2020217337A patent/AU2020217337B2/en active Active
-
2021
- 2021-01-05 US US17/142,169 patent/US11420999B2/en active Active
-
2022
- 2022-04-28 US US17/732,285 patent/US20220411469A1/en active Pending
- 2022-10-18 JP JP2022166871A patent/JP2023002671A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6811816A2 (es) | Composiciones que contienen, métodos que involucran, y usos de derivados de dolastatina unidos a aminiácidos no naturales | |
BR112013030362A2 (pt) | composições contendo, métodos envolvendo, e usos de derivados de dolastatina ligados a aminoácido não-natural | |
IL265707A (en) | Pharmaceutical preparations containing human antibodies to pcsk9 | |
CR20130529A (es) | Proteínas de fusión y vacunas de combinación que comprenden proteína e y pilina a de haemophilus influenzae | |
CL2013001947A1 (es) | Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona. | |
ZA201309287B (en) | Methods and compositions for selective regulation of protein expression | |
PL2706867T3 (pl) | Sposób wytwarzania strukturyzowanych kompozycji białkowych | |
CL2014001345A1 (es) | Metodos de tratamiento usando un anticuerpo contra interferon gamma; usos composicion farmaceutica que contiene un anticuerpo contra interferon gamma. | |
BR112014010290A2 (pt) | composição farmacêutica, métodos, composições e usos | |
CO6950485A2 (es) | Composiciones perfumantes y usos de las mismas | |
CO6950484A2 (es) | Composiciones perfumantes y usos de las mismas | |
BR112013014103A2 (pt) | método para produzir um l-aminoácido | |
MX2013002948A (es) | Composiciones farmaceuticas y nutraceuticas de acido abscisico. | |
HK1210598A1 (en) | Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation -- | |
CR20130375A (es) | Preparaciones que contienen antraquinona/formulaciones de lignina | |
BR112013022530A2 (pt) | método terapêutico homeopático e composições | |
CO6801771A2 (es) | Composición oral que comprende sodio divalproexy proceso para preparar la misma | |
IN2015DN04074A (es) | ||
UY34267A (es) | Métodos para aumentar el contenido de proteínas,aceites y/o aminoácidos en una planta | |
EP2751071A4 (en) | Fatty Acid Amide, Compositions Thereof and Method of Use Therefor | |
UY34266A (es) | Métodos para aumentar el contenido de proteínas,aceites y/o aminoácidos en una planta | |
DK2574343T3 (da) | Sammensætning til påføring på huden og anvendelse af samme | |
PT3326648T (pt) | Composições farmacêuticas que compreendem anticorpos humanos para pcsk9 | |
ZA201503455B (en) | Method for enhancing tolerance to abiotic stress in plants using carboxamide or thiocarboxamide derivatives | |
TH123117B (th) | องค์ประกอบรวมทางเภสัชกรรมที่คงสภาพ |